Literature DB >> 11802213

Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.

Nienke van der Stoep1, Paula Biesta, Edwin Quinten, Peter J van den Elsen.   

Abstract

Downregulation of major histocompatibility complex (MHC) molecules by tumor cells impairs cellular immune recognition and contributes to inefficient cell-mediated tumor eradication. Low or lack of expression of MHC molecules is frequently observed in early developmental or embryonically derived tumor cells. Considering the central role of the class II transactivator (CIITA) in MHC class II- and class I-mediated antigen presentation, we compared the induction of CIITA by interferon-gamma (IFN-gamma) in a diverse panel of developmental and more differentiated tumor cell lines. In contrast to the more differentiated tumor cell lines, none of the developmental tumor cell lines were capable of expressing CIITA after treatment with IFN-gamma. Remarkably, in transient transfection assays, CIITA promoter IV (CIITA-PIV) was found to be induced by IFN-gamma. Southern blot analysis of genomic DNA obtained from the developmental tumor cell lines indicated that the absence of endogenous CIITA induction was due to methylation of the CIITA-PIV region. Exposure to 5-azacytidine restored induction of CIITA and congruent HLA-DRA expression in these cells. The observation that only developmental tumor cell lines, originating from various tissues, employ methylation to silence CIITA expression may reflect the natural status of CIITA expression during early development rather than oncogenic transformation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11802213     DOI: 10.1002/ijc.1623

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.

Authors:  Priya Londhe; Bo Zhu; Jinu Abraham; Charles Keller; Judith Davie
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

2.  Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.

Authors:  Janet F Piskurich; Carolyn A Gilbert; Brittany D Ashley; Mojun Zhao; Han Chen; Jian Wu; Sophia C Bolick; Kenneth L Wright
Journal:  Mol Immunol       Date:  2005-06-13       Impact factor: 4.407

3.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

4.  Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.

Authors:  Han Chen; Carolyn A Gilbert; John A Hudson; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2006-06-12       Impact factor: 4.407

5.  Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

Authors:  Naoimh Herlihy; Mehmet Dogrusöz; T Huibertus van Essen; J William Harbour; Pieter A van der Velden; Marja C J A van Eggermond; Geert W Haasnoot; Peter J van den Elsen; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-15       Impact factor: 4.799

6.  Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.

Authors:  Ann C Morris; Guy W Beresford; Myesha R Mooney; Jeremy M Boss
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

7.  Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Authors:  Peter J van den Elsen; Nienke van der Stoep
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

Review 8.  HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.

Authors:  M Campoli; S Ferrone
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

Review 9.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.